Fig. 8.

Oxali-enhanced immune rejection requires NF-κB signaling. (A) Mice bearing s.c. Myc-CaP tumors generated by control and RelA-silenced cells were treated and analyzed as described in Fig. 7A. Each dot represents a treatment group mean ± SEM. (B) Single tumor cell suspensions were analyzed for H-2Kq (Left) and H-2Dd (Right) expression on CD45⁻ cells. (C) Scheme of vaccination experiments (Left). Two groups of mice were immunized with lysates of Oxali-killed shRNA-ctrl (MC^wt) or p300-silenced (MC-p300^Δ) Myc-CaP cells. After 7 d, mice were s.c. inoculated with live shRNA-ctrl (MC^wt) cells. Live shRNA-ctrl (MC^wt) cells were also implanted into nonimmunized mice as a control. Tumor growth curves are shown (Right). (A–C) Two-sided t test (means ± SEM) and two-way ANOVA were used to determine significance. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. Specific n values are shown in A–C.